Icon

OSENI (nda022426)- (EQ 25MG BASE;EQ 15MG BASE,EQ 25MG BASE;EQ 30MG BASE,EQ 25MG BASE;EQ 45MG BASE,EQ 12.5MG BASE;EQ 15MG BASE,EQ 12.5MG BASE;EQ 30MG BASE,EQ 12.5MG BASE;EQ 45MG BASE)

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE TAKEDA PHARMS USA
EQ 25MG BASE;EQ 15MG BASE,EQ 25MG BASE;EQ 30MG BASE,EQ 25MG BASE;EQ 45MG BASE,EQ 12.5MG BASE;EQ 15MG BASE,EQ 12.5MG BASE;EQ 30MG BASE,EQ 12.5MG BASE;EQ 45MG BASE
Yes No
2029-Jun-04 2018-Jan-25
None None
None No
OSENI is a combination of alogliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone, a thiazolidinedione, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
0 0 0
Total Other Developers 1
Drugs with Suitability No
EQ 25MG BASE;EQ 15MG BASE ** ** - - -
EQ 25MG BASE;EQ 30MG BASE ** ** - - -
EQ 25MG BASE;EQ 45MG BASE ** ** - - -
EQ 12.5MG BASE;EQ 15MG BASE ** ** - - -
EQ 12.5MG BASE;EQ 30MG BASE ** ** - - -
EQ 12.5MG BASE;EQ 45MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.